Human African trypanosomiasis : a guide for drug supply = Trypanosomiase humaine africaine : un guide pour l' approvisionnement en médicaments
Other TitlesTrypanosomiase humaine africaine : un guide pour l' approvisionnement en médicaments
World Health Organization. Dept. of Epidemic and Pandemic Alert and Response. (2002). Human African trypanosomiasis : a guide for drug supply = Trypanosomiase humaine africaine : un guide pour l' approvisionnement en médicaments. Geneva : World Health Organization. http://www.who.int/iris/handle/10665/67252
English / French
Gov't Doc #WHO/CDS/CSR/EPH/2001.3
MetadataShow full item record
Showing items related by title and MeSH subject.
Report on a meeting of the Product Development Team for African Trypanosomiasis Chemotherapy to review the comparative study of the 14-day versus the 7-day treatment of late stage t.b. gamiense African trypanosomiasis with eflornithine : WHO, Geneva, 14 July 1998 UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Product Development Team for African Trypanosomiasis Chemotherapy (TDR/DDR/98.1, 1998)
Control of human african trypanosomiasis: a strategy for the African Region: report of the Regional Director Regional Committee for Africa, 55 (AFR/RC55/11, 2011-06-23)1. Human African trypanosomiasis (HAT) is caused by trypanosomes that are transmitted by the tsetse fly. HAT is the only vector-borne parasitic disease with a geographical distribution limited to the African continent. Populations in the age group 15-45 years living in remote rural areas are the most affected, leading to economic loss and social misery. 2. In the early 1960s, the prevalence of HAT had been reduced to very low levels (prevalence rate less than one case per 10 000 inhabitants). Unfortunately, due to lack of regular surveillance ...